Vaginal vs Oral Utrogestan Route Selection for Luteal Phase Support and Hormone Replacement Therapy

Clinical Applications and Route Selection

The American College of Obstetricians and Gynecologists recommends vaginal Utrogestan for luteal phase support in ART cycles, with a dosage of 200mg three times daily, providing equivalent pregnancy rates and implantation rates to progesterone gel 1, 2
For threatened abortion in the first trimester, 400mg daily of vaginal Utrogestan shows high success rates of pregnancy continuation, according to the American Journal of Obstetrics and Gynecology 3, 4
The American College of Obstetricians and Gynecologists suggests that vaginal Utrogestan 200mg daily for 12-14 days monthly provides adequate endometrial protection with fewer systemic effects when used with estradiol patches for hormone replacement therapy 1, 2
For preterm birth prevention with short cervix, 100-200mg nightly of vaginal Utrogestan demonstrates a significant reduction in preterm birth <37 weeks, with a relative risk of 0.48, as reported by the American Journal of Obstetrics and Gynecology 3, 4

The standard vaginal dosing of Utrogestan is 100-200mg once or twice daily, depending on the indication, with peak concentration occurring at 2-6 hours and maintaining therapeutic levels throughout the day 1
The standard oral dosing of Utrogestan is 200-400mg daily, typically divided to minimize sedation, with peak levels occurring at 2-3 hours but requiring multiple daily doses for sustained effect 1

In patients with severe peanut allergy, vaginal micronized progesterone capsules are contraindicated because the excipients contain peanut oil; vaginal progesterone gel, which lacks peanut oil, should be used as an alternative. 5, 6

For assisted reproductive technology (ART) cycles, the regimen of 200 mg vaginal micronized progesterone capsules administered three times daily has demonstrated pregnancy and implantation outcomes equivalent to those achieved with progesterone gel, and no evidence supports the use of alternative doses or formulations. 7

Economic analyses show that vaginal micronized progesterone capsules are generally more cost‑effective than proprietary progesterone gel products for luteal phase support. 7

In pregnant individuals with a short cervical length and no prior preterm birth, nightly vaginal administration of 100–200 mg micronized progesterone reduces the risk of delivery before 37 weeks (relative risk 0.48). 8